Table of Contents

κ-Opioid Receptor Agonists Modulate Visceral Nociception at a Novel, Peripheral Site of Action

  1. G. F. Gebhart1
  1. 1Department of Pharmacology, College of Medicine, The University of Iowa, Iowa City, Iowa 52242, and
  2. 2Department of Pharmacology, University of Arizona, Tucson, Arizona 85721

Abstract

κ-opioid receptor agonists (κ-ORAs) have been shown to modulate visceral nociception through an interaction with a peripheral, possibly novel, κ-opioid-like receptor. We used in the present experiments an antisense strategy to further explore the hypothesis that κ-ORA effects in the colon are produced at a site different from the cloned κ-opioid receptor (KOR). An antisense oligodeoxynucleotide (ODN) to the cloned rat KOR was administered intrathecally (12.5 μg, twice daily for 4 d) to specifically knock-down the cloned KOR. Efficacy of the KOR antisense ODN treatment was behaviorally evaluated by assessing the antinociceptive effects of peripherally administered κ- (EMD 61,753 and U 69,593), μ- (DAMGO) and δ- (deltorphin) ORAs in the formalin test. Intrathecal antisense, but not mismatch ODN blocked the actions of EMD 61,753 and U 69,593 without affecting the actions of DAMGO or deltorphin; a complete recovery of antinociceptive actions of the κ-ORA EMD 61,753 was observed 10 d after the termination of antisense ODN treatment. In contrast, the ability of EMD 61,753 to dose-dependently attenuate responses of pelvic nerve afferent fibers to noxious colonic distension was unaffected in the same rats in which the antisense ODN effectively knocked-down the KOR as assessed in the formalin test. Additionally, Western blot analysis demonstrated a significant downregulation of KOR protein in the L4-S1 dorsal root ganglia of antisense, but not mismatch ODN-treated rats. The present results support the existence of a non-κ-opioid receptor site of action localized in the colon.

  • Received January 4, 2000.
  • Revision received May 9, 2000.
  • Accepted May 11, 2000.